New Delhi, Apr 14 (PTI) Homegrown pharma major Lupin Ltd on Thursday said it has received approval from the US health regulator to market its generic version of Desvenlafaxine extended-release tablets used for treating depression.

Also Read | Monsoon 2022 Forecast: SouthWest Monsoon Rainfall Likely To Be Normal, Says IMD.

The approval granted by the US Food and Drug Administration (FDA) is for the abbreviated new drug application (ANDA) Desvenlafaxine extended-release tablets of strength 25 mg, the company said in a regulatory filing.

Also Read | Honda City e:HEV Hybrid Unveiled in India, To Be Launched Next Month.

It is the generic equivalent of Pristiq, extended-release tablets, 25 mg of PF PRISM C.V, it added.

"The product will be manufactured at Lupin's facility in Goa, India," the company said.

Citing IQVIA MAT December 2021 data, Lupin said Desvenlafaxine extended-release tablets, 25 mg, had an estimated annual sales of USD 14 million in the US.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)